216 related articles for article (PubMed ID: 31617715)
21. Binding of a cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response.
Mast N; Zheng W; Stout CD; Pikuleva IA
J Biol Chem; 2013 Feb; 288(7):4613-24. PubMed ID: 23288837
[TBL] [Abstract][Full Text] [Related]
22. Brain Acetyl-CoA Production and Phosphorylation of Cytoskeletal Proteins Are Targets of CYP46A1 Activity Modulation and Altered Sterol Flux.
Mast N; Petrov AM; Prendergast E; Bederman I; Pikuleva IA
Neurotherapeutics; 2021 Jul; 18(3):2040-2060. PubMed ID: 34235635
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).
Mast N; Lin JB; Anderson KW; Bjorkhem I; Pikuleva IA
PLoS One; 2017; 12(10):e0187168. PubMed ID: 29073233
[TBL] [Abstract][Full Text] [Related]
24. Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.
Mast N; Charvet C; Pikuleva IA; Stout CD
J Biol Chem; 2010 Oct; 285(41):31783-95. PubMed ID: 20667828
[TBL] [Abstract][Full Text] [Related]
25. Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase.
Mast N; Liao WL; Pikuleva IA; Turko IV
Arch Biochem Biophys; 2009 Mar; 483(1):81-9. PubMed ID: 19161969
[TBL] [Abstract][Full Text] [Related]
26. Metabolism of oral turinabol by the human brain cholesterol 24-hydroxylase CYP46A1.
Putkaradze N; Hartz P; Hutter MC; Zapp J; Thevis M; Bernhardt R
J Steroid Biochem Mol Biol; 2021 Sep; 212():105927. PubMed ID: 34089835
[TBL] [Abstract][Full Text] [Related]
27. Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain.
Mast N; Norcross R; Andersson U; Shou M; Nakayama K; Bjorkhem I; Pikuleva IA
Biochemistry; 2003 Dec; 42(48):14284-92. PubMed ID: 14640697
[TBL] [Abstract][Full Text] [Related]
28. Cholesterol 24-hydroxylase: Brain cholesterol metabolism and beyond.
Moutinho M; Nunes MJ; Rodrigues E
Biochim Biophys Acta; 2016 Dec; 1861(12 Pt A):1911-1920. PubMed ID: 27663182
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.
Mast N; Anderson KW; Lin JB; Li Y; Turko IV; Tatsuoka C; Bjorkhem I; Pikuleva IA
J Biol Chem; 2017 Mar; 292(12):4913-4924. PubMed ID: 28190002
[TBL] [Abstract][Full Text] [Related]
30. Retinal Vascular Abnormalities and Microglia Activation in Mice with Deficiency in Cytochrome P450 46A1-Mediated Cholesterol Removal.
Saadane A; Mast N; Trichonas G; Chakraborty D; Hammer S; Busik JV; Grant MB; Pikuleva IA
Am J Pathol; 2019 Feb; 189(2):405-425. PubMed ID: 30448403
[TBL] [Abstract][Full Text] [Related]
31. Molecular Basis of the Recognition of Cholesterol by Cytochrome P450 46A1 along the Major Access Tunnel.
Shi N; Zheng Q; Zhang H
ACS Chem Neurosci; 2022 May; 13(10):1526-1533. PubMed ID: 35438962
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma.
Han M; Wang S; Yang N; Wang X; Zhao W; Saed HS; Daubon T; Huang B; Chen A; Li G; Miletic H; Thorsen F; Bjerkvig R; Li X; Wang J
EMBO Mol Med; 2020 Jan; 12(1):e10924. PubMed ID: 31777202
[TBL] [Abstract][Full Text] [Related]
33. The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo.
Shafaati M; Mast N; Beck O; Nayef R; Heo GY; Björkhem-Bergman L; Lütjohann D; Björkhem I; Pikuleva IA
J Lipid Res; 2010 Feb; 51(2):318-23. PubMed ID: 19474457
[TBL] [Abstract][Full Text] [Related]
34. Transcription of cytochrome P450 46A1 in NIH3T3 cells is negatively regulated by FBS.
Shinohara Y; Ando H; Maekawa M; Arai M; Horibata Y; Satou M; Jojima T; Usui I; Aso Y; Sugimoto H
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Jun; 1867(6):159136. PubMed ID: 35306146
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study.
Hurwitz SJ; Tao S; Gavegnano C; Jiang Y; Tressler RL; Tsibris A; Del Rio C; Overton ET; Lederman MM; Kantor A; Moser C; Kohler JJ; Lennox J; Marconi VC; Flexner CW; Schinazi RF
J Clin Pharmacol; 2021 Dec; 61(12):1555-1566. PubMed ID: 34169526
[TBL] [Abstract][Full Text] [Related]
36. The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj
El-Darzi N; Mast N; Li Y; Dailey B; Kang M; Rhee DJ; Pikuleva IA
Cell Mol Life Sci; 2023 Jul; 80(7):194. PubMed ID: 37392222
[TBL] [Abstract][Full Text] [Related]
37. Cholesterol-metabolizing cytochromes P450.
Pikuleva IA
Drug Metab Dispos; 2006 Apr; 34(4):513-20. PubMed ID: 16434543
[TBL] [Abstract][Full Text] [Related]
38. Allosteric activation of cytochrome P450 3A4 by efavirenz facilitates midazolam binding.
Ichikawa T; Tsujino H; Miki T; Kobayashi M; Matsubara C; Miyata S; Yamashita T; Takeshita K; Yonezawa Y; Uno T
Xenobiotica; 2018 Dec; 48(12):1227-1236. PubMed ID: 29191071
[TBL] [Abstract][Full Text] [Related]
39. Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications.
Pikuleva IA; Cartier N
Front Aging Neurosci; 2021; 13():696778. PubMed ID: 34305573
[TBL] [Abstract][Full Text] [Related]
40. Steroid and protein ligand binding to cytochrome P450 46A1 as assessed by hydrogen-deuterium exchange and mass spectrometry.
Liao WL; Dodder NG; Mast N; Pikuleva IA; Turko IV
Biochemistry; 2009 May; 48(19):4150-8. PubMed ID: 19317426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
